Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)-Reference-Cited by-同舟云学术

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

Published:2015-01-31 Issue:1 Volume:16 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Berm Elizabeth JJ,Hak Eelko,Postma Maarten,Boshuisen Marjolein,Breuning Laura,Brouwers Jacobus RBJ,Dhondt Ton,Jansen Paul AF,Kok Rob M,Maring Jan G,van Marum Rob,Mulder Hans,Voshaar Richard C Oude,Risselada Arne J,Venema Harry,Vleugel Liesbeth,Wilffert Bob

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-015-0561-0.pdf

Reference35 articles.

1. Brown PJ, Roose SP. Age and anxiety and depressive symptoms: the effect on domains of quality of life. Int J Geriatr Psychiatry. 2011;26(12):1260–6.

2. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307–11.

3. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and gender-specific prevalence of depression in latest-life - systematic review and meta-analysis. J Affect Disord. 2012;136(3):212–21.

4. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197–223.

5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications;Pharmacogenomics;2024-01

2. Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients;Pharmacogenomics and Personalized Medicine;2021-08

3. Pharmacogenomic Biomarkers and Their Applications in Psychiatry;Genes;2020-11-30

4. Pharmacogenetics in psychiatric care, a call for uptake of available applications;Psychiatry Research;2020-10

5. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?;Frontiers in Psychiatry;2020-03-12